75 activities found

  • go
  • add

Expert Perspectives: Annual Great Debates & Updates in Melanoma 2014

In the past few years, there has been an explosion of new data on efficacious targeted and immunotherapeutic approaches for the management of malignant melanoma. Multiple treatment options currently exist with potential for clinical benefit and improvement in outcomes for melanoma patients, creating the need to fully comprehend the advantages and disadvantages of the different approaches, appropriate patient subsets that benefit from therapy, optimal combinations and sequence of therapies, and integration of evidence-based strategies into traditional modalities. As new clinical findings emerge in melanoma management, several thought-provoking issues challenge the community oncologists’ perspectives in the optimal utilization of multidisciplinary approaches to treatment of the different stages of the disease. In this video discussion, Drs. John M. Kirkwood and Antoni Ribas summarize the key take-home messages on the latest advances in melanoma research presented during the Annual Great Debates and Updates in Melanoma 2014 meeting held in Phoenix, Arizona.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Expert Perspectives: 19th Annual Perspectives in Thoracic Oncology

Advances in our understanding of the molecular and genetic mechanisms underlying the pathogenesis of lung cancer have led to a dramatic expansion in the multidisciplinary approaches to the management of thoracic malignancies in the past decade with a growing number of new and improved targeted agents and efficacious combination regimens. With the advancements in the prevention, screening, and treatment of the disease, several thought-provoking issues require elucidation for thoracic oncologists to facilitate the optimal management of their patients with lung and other thoracic cancers. To further the evaluation and interpretation of emerging data, Expert Perspectives with Dr. Corey J. Langer and Dr. Anne Tsao highlights key takeaways from the 19th Annual Perspectives in Thoracic Oncology meeting.
  • Audio
  • Video
  • Text
0.25 CME
  • go
  • add

Webcast: Individualizing Therapy for Patients with Lung Cancer - What Does the Future Hold? Relating Genomics to the Potential Roles of Novel Agents

In recent years, the focus of NSCLC treatment has shifted to identifying and targeting specific tumor mutations, leading to individualized therapy. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcomes over the last several years. Despite an initial benefit from EGFR-targeted TKIs, a majority of patients treated with these agents experience cancer recurrence due to acquired drug resistance. This unavoidable challenge has led to extensive research on resistance mechanisms and other tumor mutations that could be targeted. Currently, there are several novel agents undergoing clinical trials that target different receptor tyrosine kinases (RTKs), intracellular signaling pathways, and poly ADP ribose polymerase (PARP) proteins to improve the management of advanced NSCLC. This satellite symposium, Individualizing Therapy for Patients with Lung Cancer - What does the Future Hold?, held during the 19th Annual Perspectives in Thoracic Oncology meeting aims to provide healthcare professionals a comprehensive review of the novel targeting agents in early clinical development for lung cancer.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Expert Perspectives: The Potential Impact of Molecular Profiling on Improving Clinical Outcomes for Advanced Non-small-cell Lung Carcinoma

Advances in our understanding of the molecular basis of non-small-cell lung carcinoma (NSCLC) have led to the development of effective targeted therapies, particularly tyrosine-kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR)-mutant disease. The introduction of TKIs as a treatment option, however, has led to uncertainties about their use in replacing chemotherapy and when to initiate them (first-line or second-line). Recently, the Food and Drug Administration (FDA) approved 2 real-time polymerase chain reaction (PCR) assays for the selection of TKIs (erlotinib or afatinib) as first-line treatment for advanced NSCLC patients harboring EGFR mutations. Moreover, a serum protein assay for the selection of erlotinib or chemotherapy as a second-line NSCLC treatment may likely be approved soon after promising phase III data from the PROSE trial. Expert Perspectives encompasses a video discussion that provides valuable expert opinions from Dr. Corey J. Langer and Dr. Helen Ross on the use of molecular diagnostic tests to ensure effective and personalized management of NSCLC.
  • Audio
  • Video
  • Text
0.25 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - CML

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Michael J. Mauro discuss clinical updates and late breaking abstracts for the therapy and management of patients with chronic myeloid leukemia (CML). This expert review discusses the importance of patient monitoring along with treatment options for frontline therapy and relapsed disease in an easily accessible format for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - CLL

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Neil E. Kay discuss clinical updates and late breaking abstracts for the therapy and management of patients with chronic lymphocytic leukemia (CLL). This expert review and conversation covers prognostic factors, frontline therapy and treatment options for relapsed/refractory disease that is presented in an easily accessible format for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - Multiple Myeloma

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Tomer M. Mark analyze and discuss the latest clinical data for the treatment and management of patients with multiple myeloma. This expert discussion and analysis provides updates for newly diagnosed, relapsed/refractory disease and maintenance strategies in a comprehensive, easily accessible format for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - Lymphoma

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. John P. Leonard discuss pertinent clinical data and late breaking abstracts for the management of patients with lymphoma. This expert review and discussion covers therapeutic strategies for Hodgkin lymphoma, follicular lymphoma, double hit lymphoma and mantle cell lymphoma in a concise, easily accessible format for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - MPN

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Srdan Verstovsek analyze and discuss pertinent clinical studies and late breaking updates pertaining to therapeutic strategies for the care of patients with myeloproliferative neoplasms. This engaging conversation provides updates in myelofibrosis, polycythemia vera and essential thrombocythemia in a comprehensive and easily accessible format for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the 2014 Annual Hematology Meeting - MDS, ALL, and AML

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. David P. Steensma review and discuss pertinent clinical trials and late breaking updates on therapeutic options and management strategies for patients with myelodysplastic syndromes (MDS), acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). This engaging conversation provides comprehensive and easily accessible take home points for the practicing clinician.
  • Audio
  • Video
  • Text
0.5 CME